Recent developments in antiviral drugs for cytomegalovirus

Future Virology

Volumn 6, Issue 5, 2011, Pages 633-651

  Emery, Vincent C ^a   Milne, Richard S B ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

assembly; entry inhibitor; kinetics; maturation; polymerase; protease; replication

Indexed keywords

5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; AIC 246; AMENAMEVIR; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CAPSID PROTEIN; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOPROPAVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GEFITINIB; GW 275175X; GW275175X; HEPARIN; IMIDAZOLE DERIVATIVE; LEFLUNOMIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; QUINOXALINE DERIVATIVE; TOMEGLOVIR; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CODON; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DISEASE DURATION; DNA CLEAVAGE; DNA PACKAGING; DNA REPLICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; HEMATOLOGIC DISEASE; HUMAN; HUMAN CYTOMEGALOVIRUS; IC 50; LIFE CYCLE; LUNG SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PERCEPTION DEAFNESS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; STRUCTURE ACTIVITY RELATION; TASTE DISORDER; TREATMENT RESPONSE; VIREMIA; VIRION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS MUTATION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 79957590369     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.30     Document Type: Review

References (115)

1. Griffiths PD, Baboonian C: A prospective study of primary cytomegalovirus infection during pregnancy: final report. Br. J. Obstet. Gynaecol. 91, 307-315 (1984). (Pubitemid 14132436)
2. Malm G, Engman ML: Congenital cytomegalovirus infections. Semin. Fetal Neonatal Med. 12, 154-159 (2007). (Pubitemid 46670816)
3. Rosenthal LS, Fowler KB, Boppana SB et al.: Cytomegalovirus shedding and delayed sensorineural hearing loss: results from longitudinal follow-up of children with congenital infection. Pediatr. Infect. Dis. J. 28, 515-520 (2009).
4. Kenneson A, Cannon MJ: Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 17, 253-276 (2007). (Pubitemid 47066638)
5. Kimberlin DW, Lin CY, Sanchez PJ et al.: Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143, 16-25 (2003). (Pubitemid 36928564)
6. Hilgendorff A, Daiminger A, Dangel V et al.: Oral valganciclovir treatment in a CMV congenital infected infant with sensorineural hearing loss (SNHL) first detected at 4 months of age. Klin. Padiatr. 221, 448-449 (2009).
7. Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP: New advances in the diagnosis of congenital cytomegalovirus infection. J. Clin. Virol. 41, 192-197 (2008). (Pubitemid 351246738)
8. Boppana SB, Ross SA, Novak Z et al.: Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 303, 1375-1382 (2010).
9. Fisher RA: Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl. Infect. Dis. 11, 195-202 (2009).
10. Freeman RB Jr: The 'indirect' effects of cytomegalovirus infection. Am. J. Transplant. 9, 2453-2458 (2009).
11. Ljungman P, Hakki M, Boeckh M: Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect. Dis. Clin. North Am. 24, 319-337 (2010).
12. Razonable RR: Strategies for managing cytomegalovirus in transplant recipients. Expert Opin. Pharmacother. 11, 1983-1997 (2010).
13. Boeckh M, Ljungman P: How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113, 5711-5719 (2009).
14. Jacobson MA, Mills J: Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann. Intern. Med. 108, 585-594 (1988).
15. Bowen EF, Wilson P, Cope A et al.: Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 10, 1515-1520 (1996). (Pubitemid 26370665)
16. Jabs DA: Cytomegalovirus retinitis and the acquired immunodeficiency syndrome: bench to bedside: LXVII Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 151(2), 198.EI-216.E1 (2010).
17. Compton T, Nowlin DM, Cooper NR: Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193, 834-841 (1993).
18. Feire AL, Roy RM, Manley K, Compton T: The glycoprotein B disintegrin-like domain binds b1 integrin to mediate cytomegalovirus entry. J. Virol. 84, 10026-10037 (2010).
19. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES: Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus Nature 424, 456-461 (2003).
20. Wang X, Huang DY, Huong SM, Huang ES: Integrin avb3 is a coreceptor for human cytomegalovirus. Nat. Med. 11, 515-521 (2005). (Pubitemid 40685974)
21. Kinzler ER, Compton T: Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J. Virol. 79, 7827-7837 (2005). (Pubitemid 40756817)
22. Bold S, Ohlin M, Garten W, Radsak K: Structural domains involved in human cytomegalovirus glycoprotein B-mediated cell-cell fusion. J. Gen. Virol. 77(Pt 9), 2297-2302 (1996). (Pubitemid 26316101)
23. Wang D, Shenk T: Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl Acad. Sci. USA 102, 18153-18158 (2005). (Pubitemid 41798517)
24. Ryckman BJ, Rainish BL, Chase MC et al.: Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 82, 60-70 (2008). (Pubitemid 350309123)
25. Ogawa-Goto K, Tanaka K, Gibson W et al.: Microtubule network facilitates nuclear targeting of human cytomegalovirus capsid. J. Virol. 77, 8541-8547 (2003). (Pubitemid 36871482)
26. Miller MS, Hertel L: Onset of human cytomegalovirus replication in fibroblasts requires the presence of an intact vimentin cytoskeleton. J. Virol. 83, 7015-7028 (2009).
27. Bresnahan WA, Shenk TE: UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirusinfected cells. Proc. Natl Acad. Sci. USA 97, 14506-14511 (2000). (Pubitemid 32016606)
28. Cuevas-Bennett C, Shenk T: Dynamic histone H3 acetylation and methylation at human cytomegalovirus promoters during replication in fibroblasts. J. Virol. 82, 9525-9536 (2008).
29. Pari GS, Anders DG: Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication. J. Virol. 67, 6979-6988 (1993). (Pubitemid 23343821)
30. Spector DJ, Yetming K: UL84-independent replication of human cytomegalovirus strain TB40/E. Virology 407, 171-177 (2010).
31. Kamil JP, Coen DM: Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. J. Virol. 81, 10659-10668 (2007). (Pubitemid 47463339)
32. Kuny CV, Chinchilla K, Culbertson MR, Kalejta RF: Cyclin-dependent kinase-like function is shared by the b- and g-subset of the conserved herpesvirus protein kinases. PLoS Pathog. 6, PII (2010).
33. Yu X, Shah S, Atanasov I et al.: Threedimensional localization of the smallest capsid protein in the human cytomegalovirus capsid. J. Virol. 79, 1327-1332 (2005). (Pubitemid 40053915)
34. Newcomb WW, Juhas RM, Thomsen DR et al.: The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J. Virol. 75, 10923-10932 (2001). (Pubitemid 33031559)
35. Dittmer A, Bogner E: Analysis of the quaternary structure of the putative HCMV portal protein PUL104. Biochemistry 44, 759-765 (2005). (Pubitemid 40105507)
36. Cardone G, Winkler DC, Trus BL et al.: Visualization of the herpes simplex virus portal in situ by cryo-electron tomography. Virology 361, 426-434 (2007). (Pubitemid 46574843)
37. Newcomb WW, Homa FL, Brown JC: Involvement of the portal at an early step in herpes simplex virus capsid assembly. J. Virol. 79, 10540-10546 (2005). (Pubitemid 41098593)
38. Gibson W: Structure and formation of the cytomegalovirus virion. Curr. Top. Microbiol. Immunol. 325, 187-204 (2008).
39. Welch AR, Woods AS, McNally LM, Cotter RJ, Gibson W: A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc. Natl Acad. Sci. USA 88, 10792-10796 (1991). (Pubitemid 21915924)
40. Welch AR, McNally LM, Hall MR, Gibson W: Herpesvirus proteinase: site-directed mutagenesis used to study maturational, release, and inactivation cleavage sites of precursor and to identify a possible catalytic site serine and histidine. J. Virol. 67, 7360-7372 (1993). (Pubitemid 23343864)
41. Chen P, Tsuge H, Almassy RJ et al.: Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell 86, 835-843 (1996). (Pubitemid 26303451)
42. Shieh HS, Kurumbail RG, Stevens AM et al.: Three-dimensional structure of human cytomegalovirus protease. Nature 383, 279-282 (1996). (Pubitemid 26317681)
43. Qiu X, Culp JS, DiLella AG et al.: Unique fold and active site in cytomegalovirus protease. Nature 383, 275-279 (1996). (Pubitemid 26317680)
44. Tong L, Qian C, Massariol MJ, Bonneau PR, Cordingley MG, Lagace L: A new serineprotease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 383, 272-275 (1996). (Pubitemid 26317679)
45. Batra R, Khayat R, Tong L: Molecular mechanism for dimerization to regulate the catalytic activity of human cytomegalovirus protease. Nat. Struct. Biol. 8, 810-817 (2001). (Pubitemid 32803602)
46. Dittmer A, Drach JC, Townsend LB, Fischer A, Bogner E: Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-d-ribonucleosides. J. Virol. 79, 14660-14667 (2005). (Pubitemid 41636264)
47. Thoma C, Borst E, Messerle M, Rieger M, Hwang JS, Bogner E: Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus. Biochemistry 45, 8855-8863 (2006). (Pubitemid 44100681)
48. Scholz B, Rechter S, Drach JC, Townsend LB, Bogner E: Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res. 31, 1426-1433 (2003). (Pubitemid 36304904)
49. Nadal M, Mas PJ, Blanco AG et al.: Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain. Proc. Natl Acad. Sci. USA 107, 16078-16083 (2010).
50. Miller MS, Furlong WE, Pennell L, Geadah M, Hertel L: RASCAL is a new human cytomegalovirus-encoded protein that localizes to the nuclear lamina and in cytoplasmic vesicles at late times postinfection. J. Virol. 84, 6483-6496 (2010).
51. Dal MP, Pignatelli S, Zini N et al.: Analysis of intracellular and intraviral localization of the human cytomegalovirus UL53 protein. J. Gen. Virol. 83, 1005-1012 (2002). (Pubitemid 34477272)
52. Browne H, Bell S, Minson T, Wilson DW: An endoplasmic reticulum-retained herpes simplex virus glycoprotein H is absent from secreted virions:evidence for reenvelopment during egress. J. Virol. 70, 4311-4316 (1996). (Pubitemid 26187432)
53. Skepper JN, Whiteley A, Browne H, Minson A: Herpes simplex virus nucleocapsids mature to progeny virions by an envelopment - deenvelopment - reenvelopment pathway. J. Virol. 75, 5697-5702 (2001). (Pubitemid 32488165)
54. Buser C, Walther P, Mertens T, Michel D: Cytomegalovirus primary envelopment occurs at large infoldings of the inner nuclear membrane. J. Virol. 81, 3042-3048 (2007). (Pubitemid 46447071)
55. Baines JD, Hsieh CE, Wills E, Mannella C, Marko M: Electron tomography of nascent herpes simplex virus virions. J. Virol. 81, 2726-2735 (2007). (Pubitemid 46447037)
56. Cepeda V, Esteban M, Fraile-Ramos A: Human cytomegalovirus final envelopment on membranes containing both trans-Golgi network and endosomal markers. Cell Microbiol. 12, 386-404 (2010).
57. Tooze J, Hollinshead M, Reis B, Radsak K, Kern H: Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur. J. Cell Biol. 60, 163-178 (1993). (Pubitemid 23092674)
58. Tandon R, AuCoin DP, Mocarski ES: Human cytomegalovirus exploits ESCRT machinery in the process of virion maturation. J. Virol. 83, 10797-10807 (2009).
59. Mendelson M, Monard S, Sissons P, Sinclair J: Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J. Gen. Virol. 77(Pt 12), 3099-3102 (1996). (Pubitemid 27056530)
60. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH: Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl Acad. Sci. USA 102, 4140-4145 (2005). (Pubitemid 40388569)
61. Pescovitz MD: Valganciclovir: recent progress. Am. J. Transplant. 10, 1359-1364 (2010).
62. Hodson EM, Craig JC, Strippoli GF, Webster AC: Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. CD003774 (2008).
63. Paya C, Humar A, Dominguez E et al.: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4, 611-620 (2004). (Pubitemid 38523584)
64. Humar A, Lebranchu Y, Vincenti F et al.: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am. J. Transplant. 10, 1228-1237 (2010).
65. Asberg A, Humar A, Rollag H et al.: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 7, 2106-2113 (2007). (Pubitemid 47247057)
66. Baldanti F, Lurain N, Gerna G: Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum. Immunol. 65, 403-409 (2004). (Pubitemid 38686763)
67. Scarlett JM, Zhu X, Enriori PJ et al.: Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation. Endocrinology 149, 4837-4845 (2008).
68. Ljungman P, Hakki M, Boeckh M: Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect. Dis. Clin. North Am. 24, 319-337 (2010).
69. Nassetta L, Kimberlin D, Whitley R: Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J. Antimicrob. Chemother. 63, 862-867 (2009).
70. Mercorelli B, Oreste P, Sinigalia E et al. : Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 54, 4561-4567 (2010).
71. English EP, Chumanov RS, Gellman SH, Compton T: Rational development of b-peptide inhibitors of human cytomegalovirus entry. J. Biol. Chem. 281, 2661-2667 (2006). (Pubitemid 43845728)
72. Bloom JD, Dushin RG, Curran KJ et al.: Thiourea inhibitors of herpes viruses. Part 2: N-benzyl-N'-arylthiourea inhibitors of CMV. Bioorg. Med. Chem. Lett. 14, 3401-3406 (2004). (Pubitemid 38737135)
73. de Castro CS, Peromingo MT et al.: 4''-benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action. J. Med. Chem. 51, 5823-5832 (2008).
74. Chono K, Katsumata K, Kontani T et al. : ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicellazoster virus and herpes simplex virus types 1 and 2. J. Antimicrob. Chemother. 65, 1733-1741 (2010).
75. Chen X, Adrian J, Cushing T et al.: SAR studies on a novel series of human cytomegalovirus primase inhibitors. Bioorg. Med. Chem. Lett. 17, 2188-2192 (2007). (Pubitemid 46484317)
76. Liu S, Knafels JD, Chang JS et al.: Crystal structure of the herpes simplex virus 1 DNA polymerase. J. Biol. Chem. 281, 18193-18200 (2006). (Pubitemid 44035619)
77. Appleton BA, Brooks J, Loregian A, Filman DJ, Coen DM, Hogle JM: Crystal structure of the cytomegalovirus DNA polymerase subunit UL44 in complex with the C terminus from the catalytic subunit. Differences in structure and function relative to unliganded UL44. J. Biol. Chem. 281, 5224-5232 (2006). (Pubitemid 43847787)
78. Loregian A, Coen DM: Selective anticytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem. Biol. 13, 191-200 (2006). (Pubitemid 43255591)
79. Beadle JR, Hartline C, Aldern KA et al.: Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46, 2381-2386 (2002). (Pubitemid 34793439)
80. Kern ER, Bidanset DJ, Hartline CB, Yan Z, Zemlicka J, Quenelle DC: Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 48, 4745-4753 (2004). (Pubitemid 39577680)
81. Gentry BG, Kamil JP, Coen DM, Zemlicka J, Drach JC: Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir. Antimicrob. Agents Chemother. 54, 3093-3098 (2010).
82. Chou S, Bowlin TL: Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob. Agents Chemother. 55, 382-384 (2011).
83. Schnute ME, Brideau RJ, Collier SA et al.: Synthesis of 4-oxo-4,7-dihydrofuro[2,3-b] pyridine-5-carboxamides with broadspectrum human herpesvirus polymerase inhibition. Bioorg. Med. Chem. Lett. 18, 3856-3859 (2008).
84. Tanis SP, Strohbach JW, Parker TT et al.: The design and development of 2-aryl-2- hydroxy ethylamine substituted 1H,7Hpyrido[ 1,2,3-de]quinoxaline-6- carboxamides as inhibitors of human cytomegalovirus polymerase. Bioorg. Med. Chem. Lett. 20, 1994-2000 (2010).
85. Nieman JA, Nair SK, Heasley SE et al.: Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubility. Bioorg. Med. Chem. Lett. 20, 3039-3042 (2010).
86. Chou S, Marousek GI: Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob. Agents Chemother. 50, 3470-3472 (2006). (Pubitemid 44527529)
87. Prichard MN: Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol. 19, 215-229 (2009).
88. Trofe J, Pote L, Wade E, Blumberg E, Bloom RD: Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann. Pharmacother. 42, 1447-1457 (2008).
89. Shannon-Lowe CD, Emery VC: The effects of maribavir on the autophosphorylation of ganciclovir resitant mutants of the cytomegalovirus UL97 protein. Herpesviridae 1, 4 (2010).
90. Winston DJ, Young JA, Pullarkat V et al.: Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebocontrolled, dose-ranging study. Blood. 111, 5403-5410 (2008).
91. Marty FM, Ljungman P, Papanicolaou GA et al.; for the Maribavir 1263-300 Clinical Study Group: Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a Phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 4, 284-292 (2011).
92. Strasfeld L, Lee I, Tatarowicz W, Villano S, Chou S: Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J. Infect. Dis. 202, 104-108 (2010).
93. Schleiss M, Eickhoff J, Auerochs S et al.: Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo. Antiviral Res. 79, 49-61 (2008).
94. Borthwick AD, Angier SJ, Crame AJ et al.: Design and synthesis of pyrrolidine-5,5-translactams (5-oxo-hexahydro-pyrrolo[3,2-b] pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The a-methyl-trans-lactam template. J. Med. Chem. 43, 4452-4464 (2000). (Pubitemid 32046870)
95. Borthwick AD, Exall AM, Haley TM, Jackson DL, Mason AM, Weingarten GG: Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability. Bioorg. Med. Chem. Lett. 12, 1719-1722 (2002). (Pubitemid 34626894)
96. Borthwick AD, Crame AJ, Ertl PF et al.: Design and synthesis of pyrrolidine-5,5-translactams (5-oxohexahydropyrrolo[3,2-b] pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality. J. Med. Chem. 45, 1-18 (2002). (Pubitemid 34038539)
97. Borthwick AD, Davies DE, Ertl PF et al.: Design and synthesis of pyrrolidine-5,5'-translactams (5-oxo-hexahydropyrrolo[3,2-b] pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability. J. Med. Chem. 46, 4428-4449 (2003). (Pubitemid 37238746)
98. Borthwick AD: Design of translactam HCMV protease inhibitors as potent antivirals. Med. Res. Rev. 25, 427-452 (2005). (Pubitemid 40946535)
99. Gerona-Navarro G, Perez de Vega MJ, Garcia-Lopez MT et al.: Synthesis and anti-HCMV activity of 1-acyl-b-lactams and 1-acylazetidines derived from phenylalanine. Bioorg. Med. Chem. Lett. 14, 2253-2256 (2004). (Pubitemid 38481400)
100. Gerona-Navarro G, Perez de Vega MJ, Garcia-Lopez MT et al.: From 1-acyl-blactam human cytomegalovirus protease inhibitors to 1- benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors. J. Med. Chem. 48, 2612-2621 (2005). (Pubitemid 40516450)
101. Gopalsamy A, Lim K, Ellingboe JW et al.: Design and syntheses of 1,6-naphthalene derivatives as selective HCMV protease inhibitors. J. Med. Chem. 47, 1893-1899 (2004). (Pubitemid 38453909)
102. Jiang X, Bai Y, Rider P et al.: Engineered external guide sequences effectively block viral gene expression and replication in cultured cells. J. Biol. Chem. 286, 322-330 (2011).
103. Underwood MR, Harvey RJ, Stanat SC et al.: Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72, 717-725 (1998). (Pubitemid 28048891)
104. Underwood MR, Ferris RG, Selleseth DW et al.: Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob. Agents Chemother. 48, 1647-1651 (2004). (Pubitemid 38544370)
105. Hwang JS, Schilf R, Drach JC, Townsend LB, Bogner E: Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole d-ribonucleosides. Antimicrob. Agents Chemother. 53, 5095-5101 (2009).
106. Waldman WJ, Knight DA, Blinder L et al.: Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 42, 412-418 (1999). (Pubitemid 30122078)
107. Avery RK, Mossad SB, Poggio E et al.: Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 90, 419-426 (2010).
108. John GT, Manivannan J, Chandy S et al.: A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant. Proc. 37, 4303-4305 (2005). (Pubitemid 43016014)
109. Battiwalla M, Paplham P, Almyroudis NG et al.: Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl. Infect. Dis. 9, 28-32 (2007).
110. Reefschlaeger J, Bender W, Hallenberger S et al.: Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48, 757-767 (2001). (Pubitemid 33735310)
111. Lischka P, Hewlett G, Wunberg T et al.: In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54, 1290-1297 (2010).
112. Kaptein SJ, Efferth T, Leis M et al.: The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res. 69, 60-69 (2006). (Pubitemid 43152041)
113. Shapira MY, Resnick IB, Chou S et al.: Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 46, 1455-1457 (2008). (Pubitemid 351589951)
114. Arav-Boger R, He R, Chiou CJ et al.: Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared with artemisinin monomers. PLoS One 5, E10370 (2010).
115. Efferth T, Marschall M, Wang X et al.: Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovirresistant human cytomegaloviruses. J. Mol. Med. 80, 233-242 (2002). (Pubitemid 34439295)